Have Questions? Call Us Toll Free (877) 880-5251

Eye implant to treat wet macular degeneration approved by FDA

Pharmaceutical company, Genetech, recently announced the FDA's approval of their new port delivery system, Susvimo, for the treamtment of wet age-related macular degeneration.

Susvimo is a refillable eye implant that requires a single outpatient

procedure to place the device under the upper eyelid. The device is the size of a grain of rice and is refilled every six months with Regeneron's anti-VEGF treatment, Lucentis.

This new therapy allows patients an alternative to the current intravitreal injections which are administered every 4 to 8 weeks. The frequency and cost of the injections often contributes to non-compliance among patients.

In clinical trials, Susvimo was well-tolerated and more than 98% of patients were able to go up to six months between refills.

Search VisiVite